(Q37387955)

20 August 2017

1 reference

title

Concepts of induction and escalation therapy in multiple sclerosis (English)

1 reference

20 August 2017

0 references

Peter Rieckmann

1

1 reference

20 August 2017

publication date

1 February 2009

1 reference

Journal of the Neurological Sciences

20 August 2017

published in

1 reference

20 August 2017

volume

277 Suppl 1

1 reference

20 August 2017

page(s)

S42-5

1 reference

The natural history of multiple sclerosis

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Natural history of secondary-progressive multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

New options for early treatment of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Induction versus escalation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Intensive immunosuppression in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Medical treatment of juvenile idiopathic arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Challenges in the management of microscopic polyangiitis: past, present and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Treatment of acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Immunosuppression followed by immunomodulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Long-term experience with induction treatment regimens in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970012-7

10.1016/S0022-510X(09)70012-7

7 January 2021

Identifiers

DOI

1 reference

20 August 2017

1 reference